https://doi.org/10.4081/bse.182

V-ATPase as a mediator of treatment resistance in Glioblastoma Multiforme: an in vitro study to investigate new therapeutic strategies

Vol. 2 No. 1 (2021)
Published: 29 September 2021
GBM, GSC, V-ATPase, Baf-A1
Abstract Views: 303
PDF: 192
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Eleonora Messuti
e.messuti@campus.unimib.it
University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy.
Martina Giambra
University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy.
Serena Redaelli
University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy.
Andrea Di Cristofori
San Gerardo Hospital, ASST Monza, Neurosurgery Unit, Monza, Italy.
Carlo Giussani
San Gerardo Hospital, ASST Monza, Neurosurgery Unit, Monza, Italy.
Angela Bentivegna
University of Milano-Bicocca, School of Medicine and Surgery, Monza, Italy.

Recent evidences suggest the involvement of the Vacuolar H+ ATPase (V-ATPase) in the development and/or progression of Glioblastoma Multiforme (GBM). This proton pump could be a valid therapeutic target but more in-depth studies are necessary. The aim of this study is to better define the in vitro effects on Glioma Stem Cell (GSC) primary cultures viability of single and combined treatment with Bafilomycin-A1 (Baf-A1), a V-ATPase inhibitor, and Temozolomide (TMZ), the chemotherapeutic agent currently used to treat GBM patients. We found out that GSC were resistant to TMZ and more sensitive to treatments with Baf-A1 and that the two drugs exerted a synergistic effect when administered together.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Messuti, E., Giambra, M., Redaelli, S., Di Cristofori, A. ., Giussani, C., & Bentivegna, A. (2021). V-ATPase as a mediator of treatment resistance in Glioblastoma Multiforme: an <em>in vitro</em> study to investigate new therapeutic strategies. Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.182

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Most read articles by the same author(s)